Compared to healthy controls, serum suPAR levels were significantly elevated in SLE patients. No association was recorded regarding suPAR levels and SLE disease activity in cross-sectional or consecutive samples. However, a strong association was observed between suPAR and SDI (p<0.0005). Considering distinct SDI domains, renal, neuropsychiatric, ocular, skin and peripheral vascular damage had significant impact on suPAR levels.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a rheumatic disease characterized by multi-organ involvement with episodes of disease flares and remission over time. The pathogenesis is believed to relate to abnormal apoptosis and deficient elimination of apoptotic material, such as nuclear proteins and nucleic acids, eventually leading to autoantibody production and formation of circulating or tissue-bound immune complexes. 1 Autoantibody-binding to tissueexposed autoantigens and/or insufficient receptor-mediated clearance of circulating immune complexes via the reticuloendothelial system are explanations to extrahepatic immune complex formation/deposition. [2] [3] [4] Although autoantibodies, complement proteins, blood cell counts and erythrocyte sedimentation rate (ESR) can be helpful markers of diagnosis, prognosis, and/or degree of ongoing inflammation, distinction of disease activity from irreversible organ damage remains a challenge. 5 C-reactive protein (CRP) is usually a reliable marker of systemic inflammation, but this is not the case in SLE 6, 7 or viral infections 8 probably due to interferon alpha (IFN dependent inhibition of hepatic CRP production. 9 Other biomarkers may reflect specific organ involvements, most notably lupus nephritis which is often mirrored by raised levels of autoantibodies against double-stranded (ds) DNA, nucleosomes and/or complement protein (C) 1q. 2, 5, 10 The Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index (SDI) 11 covers 12 organ systems and measures accumulated organ damage that has occurred since the onset of SLE. SDI is scored regardless of whether the damage can be attributed to SLE or to other causes. A limited number of cross-sectional studies have demonstrated associations between certain biomarkers (e.g. apoptosis stimulating fragment (Fas/CD95), both membrane bound and soluble (sFas), CRP and osteopontin), and organ damage. [12] [13] [14] [15] However, only plasma levels of osteopontin have been shown predict organ damage, and this was shown for a relatively small study group of SLE patients. 15 Soluble urokinase plasminogen activator receptor (suPAR) is part of the plasminogen activation system and is involved in inflammation, tissue remodeling and cancer metastasis. 16 Many cell types express uPAR (CD87), including vascular smooth muscle cells, 17 16, 27 In the first studies on circulating suPAR, levels were found to be elevated and to predict disease outcome in various forms of cancer and infectious diseases. 16, 28 It has also been suggested to be a biomarker of value in rheumatoid arthritis, 29 and to reflect organ damage in liver and kidney disease. [30] [31] [32] The aims of the present study were to investigate if circulating suPAR reflects inflammatory activity and/or organ damage in lupus. 
METHODS

Patients and controls
Routine laboratory analyses
At all visits, laboratory analyses included blood cell count (erythrocytes, leukocytes and 
suPAR and cytokine analyses
For suPAR analyses sera were diluted 1:100 and assayed in duplicates by enzyme-linked immunosorbent assay (ELISA) (ViroGates, Copenhagen, Denmark; kindly provided by Electra-Box AB, Tyresö, Sweden). Serum samples from SLE patients and healthy controls were interdispersed on the multi-well plates to avoid biased results due to inter-assay variation. IL-1 receptor antagonist (IL-1ra) was analyzed by a commercial ELISA from R&D Systems (Abingdon, UK). IFN was measured by a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) at Uppsala university, Sweden. 36 In sera from 155 of the patients fulfilling the 1982 ACR classification criteria, IL-10, IL-6, IL-1 and TNF were analyzed with a high sensitivity multiplex magnetic bead assay (Milliplex, Millipore, Solna, Sweden).
Statistics
Relations between disease activity or organ damage with suPAR or CRP were assessed using multiple linear regression models with suPAR or log-transformed CRP as the response variables. Because of known or potential age-and sex-dependent variations of suPAR 37 and CRP 38 levels, age and sex were included as independent variables for all multiple linear regression analyses with suPAR or logCRP as the dependent variable. Due to significant age and sex differences between the healthy controls and patients, univariate analysis of variance with adjustment for age and sex was used to assess differences between these groups.
Since 19% of the patients only met the Fries criteria, all statistical analyses were run for (1) all patients, and (2) only the patients fulfilling ACR-82.
Fisher's exact test or the Mann whitney U test was used to determine differences in disease characteristics between patients fulfilling ACR-82 and patients only meeting the Fries criteria.
Wilcoxon matched-paired sign rank test was used to compare individual differences in suPAR level at lowest and highest disease activity.
A two-tailed p-value of <0.05 was considered significant. All statistical analyses were performed with the SPSS Statistics 19-20 (IBM, Armonk, NY, USA) or GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA, USA) softwares.
Ethics
Informed consent was obtained from all subjects. The study protocol was approved by the regional ethics committee in Linköping (M75-08/2008).
RESULTS
Associations of suPAR with cytokines and routine laboratory measures
As shown in Table 2 , suPAR levels were positively associated with all cytokines measured apart from IL-6. suPAR was positively associated with creatinine, CRP, ESR, leukocyte count, platelet count, C4 and urine albumin, whereas it was inversely associated with erythrocyte count. In addition, among patients fulfilling ACR-82, C3 and urine erythrocytes were also positively associated with suPAR. 
suPAR versus SLE disease activity
The difference between healthy controls (n=100) and SLE patients at baseline (n=198) regarding suPAR levels was only borderline significant (p=0.050) (Figure 1 ). However, when excluding patients with leukocytopenia (<3.5x10 9 /L) at sampling the difference was statistically significant (p=0.034). Because of a relatively low average SLE disease activity at baseline, we also compared suPAR levels in patients with active disease at baseline (PGA≥2, n=16) with healthy controls, and then found a significant difference (p=0.004). In the regression analysis, there was no significant association between suPAR levels and disease activity, neither defined as SLEDAI-2K (all patients: p=0.84; ACR-82 patients:
p=0.71, respectively) nor as PGA (all patients: p=0.20; ACR-82 patients: p=0.34, respectively). uPAR is expressed and shed from immune cells, and since SLE patients often present with cytopenia, we also included leukocyte count and platelet count as independent variables in the regression analysis, but still without significant association of suPAR with disease activity. Finally, we also included prednisolone dose into the regression analysis, but without receiving a significant association (not shown).
Association of CRP and suPAR with organ damage
The mean SDI for all SLE patients was 1.1 ± 1.6 and the median value was 0 (range 0-8). The organs affected are presented in Table 1 . The relation between SDI and suPAR is shown in Figure 2 and the statistical association assessed by multiple linear regression is shown in Table 3 . A highly significant positive association was found between suPAR and organ damage (p<0.0005) as well as a borderline significant association between logCRP and SDI (p=0.05, =0.14), the latter not significant when the study population was limited to ACR-82
only. Dissecting SDI into organ systems in a multiple regression analysis, we found renal (p<0.0005), ocular (p<0.0005) neuropsychiatric (p<0.0005), skin (p=0.001) and peripheral vascular (p=0.019) organ damage to have a significant positive impact on suPAR levels, whereas no isolated organ affection had any significant impact on CRP levels. Adjustments for cell counts and prednisolone dose did not reveal any important changes in the association between SDI and suPAR (Table 3) , whereas adjustment for prednisolone dose and/or cell counts eliminated the significant association between CRP and total SDI found for all patients (n=198) (not shown). 
Individual suPAR level variations in consecutive samples
For the 18 patients where consecutive serum samples were analyzed, the suPAR level at the lowest and highest recorded disease activity was compared (Figure 3 ). No significant difference was seen (p=0.542). 
Few extreme drops in suPAR level over time in consecutive samples
The maximum drop in suPAR level during the study period was calculated for each of the 18 patients that were monitored consecutively. Maximum drop was defined as the greatest decline in suPAR over time. The median value of maximum drop was 0.6 ng/mL (range 0-20.7 ng/mL). Two patients had extreme drops in suPAR levels (9.4 ng/mL and 20.7 ng/mL, respectively) compared to the others (≤2.2 ng/mL). The patient representing the second highest suPAR drop had a viral infection and a minor myocardial infarction at the time point of the high suPAR level, whereas the patient with the highest drop had no known infection or other signs of active disease at the time of high serum suPAR level.
DISCUSSION
SLE is a profoundly heterogeneous disease entity. It therefore appears unlikely that one single biomarker could cover all lupus phenotypes and serve as a general disease activity or severity marker. Nevertheless, suPAR has emerged as a biomarker reflecting inflammatory activity and predicting outcome in several infectious and malignant diseases. We found it worthwhile to evaluate the potentials of suPAR as a biomarker in SLE since earlier observations have been contradictory. 39, 40 Based on the results of this study, we conclude that circulating suPAR is an unreliable marker of SLE disease activity. However, we found that the level appears to reflect irreversible organ damage, especially in the renal, ocular and neuropsychiatric domains of SDI.
Lupus patients commonly present with cytopenia and we found that suPAR levels strongly associated with leukocyte count in line with previous observations. 41 Thus, it is likely that the absence of a general increase in suPAR levels among SLE patients could be a reflection of decreased leukocyte count (Figure 1 ). Many cytokines and routine laboratory measures were associated with suPAR (Table 2) . Convincing correlations between suPAR and the proinflammatory cytokines IL-1 and TNF as well as CRP and creatinine have been shown also in other conditions, 29, [41] [42] [43] and could be expected since uPAR is up-regulated and shed from immune cells during inflammation. Interestingly, suPAR levels were not inversely associated with complement proteins or complement function, which further demonstrates a lack of apparent association between suPAR and disease activity in lupus.
To our knowledge, no biomarkers apart from lymphocyte Fas expression, 14 sFas, 12 CRP 13 , and osteopontin 15 have been shown to associate with organ damage as defined by SDI.
Importantly, age has been found to correlate with levels of sFas, but the associations with organ damage in the Fas and sFas studies were not adjusted for age. Lee and collaborators found CRP to be associated with pulmonary, musculoskeletal and global SDI in a crosssectional study involving 610 SLE patients. 13 In line with their results, we identified a weak association of CRP with global SDI, but in contrast to the study by Lee et al., we found no significant impact of isolated organ systems on CRP levels. This discrepancy can possibly be due to differences in study size and ethnicity, but may also be explained by differences in statistical adjustments made in the regression analyses.
Due to its reflection of permanent organ damage, one would expect suPAR levels to be stable over time, apart from further raised levels upon additional organ damage. In fact, suPAR levels fluctuated moderately over time in patients followed longitudinally. Although the median value regarding maximal drop in suPAR was very low, two patients showed a substantial decline in suPAR over time. A plausible explanation was found only for one of these patients who had an ongoing infection at the time of high suPAR level. Age and lifestyle factors such as smoking and physical activity have impact on baseline suPAR levels in a healthy population. 43 These factors, however, appear unlikely as explanations to such great variations, in particular since this patient was not unique regarding disease manifestations or medication.
Some affected organ systems were associated with suPAR levels when the score was divided into specific domains. However, the lack of association with other domains is most likely due to lack of power in the statistical analysis and not necessarily to an absence of association with suPAR. Of all organ systems considered, renal damage had the most pronounced impact on suPAR levels. Interestingly, SDI of the renal domain has previously shown to predict mortality in SLE patients. 44, 45 In addition, several studies have shown a convincing correlation between SDI and severe outcome of the disease, particularly if damage occurs early. 44, [46] [47] [48] Two other domains also significantly associated with suPAR levels in the regression analyses were neuropsychiatry and skin. Interestingly, expression of uPAR has been reported to be increased in the frontal cortex of patients with epilepsy. 49 It is also possible that urokinase-type plasminogen activator and uPAR synergetically contributes to extensive alopecia, epidermal thickening and subepidermal blisters. 50 One study reported that raised suPAR levels predict mortality, not only in patients with severe diseases, but also in apparently healthy subjects. 37 Hypothetically, permanently raised levels of circulating suPAR in SLE may thus be a subtle sign of deteriorated health and outcome regardless of current disease activity.
Further research is needed to understand the biological roles of suPAR, its turnover in health and different diseases, as well as to pinpoint potential pitfalls in the use of suPAR as a biomarker. Besides its role in the plasminogen activation system, where urokinase-type plasminogen activator is one of the serine proteases generating plasmin that degrades fibrin, suPAR/uPAR seems to be involved in a number of immune regulation mechanisms, including cell migration and adhesion. 16 Regarding organ damage in the present as well as in previous studies, 30, 31 it is not known whether suPAR exerts a direct harmful effect or if it just reflects damage. Since suPAR levels correlate strongly to leukocyte counts in inflammation, it is interesting to note that neutrophils may be stimulated in vitro to release the chemotactic suPAR form D II-III , that is capable of causing a formyl peptide receptor-like 1-dependent migration of e.g. transfected kidney cells. 51 Synovial fluid neutrophils from rheumatoid arthritis patients also release more D II-III than peripheral neutrophils, 52 further supporting a role for suPAR in recruiting formyl-peptide receptor expressing cells at inflammatory sites.
suPAR also interacts with integrins, and kidney damage in focal segmental glomerulosclerosis was recently suggested to be due to a direct effect on podocyte behaviour via integrin  3  v . 32 This interesting finding is currently under debate. 53, 54 Another observation making uPAR particularly interesting in relation to SLE is that uPAR stimulates efferocytosis, i.e.
phagocytic uptake of apoptotic cells, 55 including apoptotic neutrophils. 56 Briassouli et al. also recently suggested that there is an interaction between the SLE-associated autoantigen Ro60
and uPAR, and that autoantibodies against Ro60 may promote enhanced uPAR expression and interfere with efferocytosis of apoptotic fetal cardiocytes. 57 The same authors also recently suggested that an autoantibody-triggered uPAR-dendent increase in plasmin activity may activate transforming growth factor-β, which in turn could promote fibrosis. 58 Speculatively, altered expression/shedding of uPAR may be affected by autoantibodies and reflect, or even contribute to, a deficient waste disposal process.
In conclusion, circulating suPAR reflects disease severity/organ damage in SLE and is thus a promising biomarker candidate. However, further prospective studies are warranted to (i)
answer the question of whether suPAR not only reflects prevalent tissue damage, but also predicts risk of future organ damage; as well as to (ii) understand the biological relevance of raised suPAR levels in SLE patients with severe disease.
